MedTrace Logo

Blood Ropivacaine Concentrations Following Chest Wall Nerve Block Continuous Infusion

NCT02860091 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2026-05-18

No results posted yet for this study

Summary

The main objective of this proposed investigation is to evaluate blood ropivacaine concentrations in infants and toddlers following the initiation of, and over the course of, continuous paravertebral nerve blockade using ropivacaine infusion for postoperative pain control following esophageal atresia repair procedures that include posterior tracheopexy.

Continuous unilateral chest wall nerve blockade (CUCWNB) using ropivacaine is the current standard of practice for this surgical population at the investigators' institution and, as such, this study does not aim to alter the current standard clinical care received by participants but rather evaluate the blood concentrations of ropivacaine as it is routinely used.

Conditions

  • Pain, Postoperative

Interventions

DRUG

Ropivacaine infusion

Delivered via paravertebral nerve block catheter.

Sponsors & Collaborators

Principal Investigators

  • ROLAND BRUSSEAU · Boston Children's Hospital

Eligibility

Max Age
4 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2026-05-14
Completion
2026-05-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02860091 on ClinicalTrials.gov